The follow-up results of our untreated pati̇ents fi̇rst di̇agnosed as pri̇mary i̇mmune thrombocytopeni̇a

Immune thrombocytopenia aredivided into two groups based on factors that play a role in the etiology as primary and secondary immune thrombocytopenia. Accordingly, Primary immune thrombocytopenia (ITP) is an autoimmune disease that can be diagnosed by exclusion of isolated thrombocytopenia (<100x109 / L) (eukocytes and hemoglobin values were normal) and other causes of thrombocytopenia. Main purpose of therapy is to be able to achieve platelet levels that can prevent major bleeding rather than normal levels of platelets in ITP patients. Today, treatment indications in newly diagnosed ITP patients are platelet count of <30x109 / L and platelet count of 30-100 x 109 / L with clinically significant haemorrhage. In our study, treatment was applied to patients with these indications. A total of 205 newly diagnosed ITP patients were retrospectively evaluated in this study; primary treatment was applied to 126 patients (61.5%) after diagnosis and 79 patients (38.5%) were followed without treatment. After ITP diagnosis corticosteroid therapy was started for various reasons at a mean of 17.9 months (1-60 months) of follow-up at 24 (30.4%) of 79 patients who were followed without treatment. In most of these 24 patients who were started on treatment within the follow-up period (13 patients) indications occurred in the first year of treatment, the number of patients who were started on treatment in the subsequent years decreased gradually. In 12 (50%) of 24 patients who were treated, treatment was applied due to the platelet counts lower than 30x109 / L and surgery or childbirth (50%) although platelet counts higher than 30x109 / L.With the deepening of thrombocytopenia (<30x109 / L) treatment was initiated in 12 patients were treated until the mean time of 10 months. Of these patients, 9 (75%) treatment was started within the first 12 months following the diagnosis of ITP.In the literature treatment followed newly diagnosed adult ITP patients with natural course due to a lack of data on this age group ITP patients how to watch the number of platelets in the long-term follow-up in, the treatment rate and treatment follow-up is still a lack of information about what happened.Therefore, the most important scope of this study was to evaluate the results of our patients followed without treatment after diagnosis of ITP. In the vast majority of newly diagnosed untreated ITP patients followed in our study (85%) platelet counts remained relatively stable in the follow-up period and treatment was started to a small number of patients with deepening of thrombocytopenia. Mean duration to the beginning of treatment at these patients were found as 10 months (1-58 months) and 9 (75%) of these patients were started on treatment at the first 12 months. However, our small number of patients followed without any treatment and short follow times are limitations of our study. Therefore comprehensive studies with longer follow-up periods are needed to strengthen our findings.